Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00407485
Other study ID # NCI-2012-02840
Secondary ID NCI-2012-02840PH
Status Completed
Phase Phase 2
First received December 4, 2006
Last updated October 10, 2014
Start date November 2006
Est. completion date April 2014

Study information

Verified date October 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor.


Description:

PRIMARY OBJECTIVES:

I. Determine the response rate in patients with recurrent, locoregionally advanced, or metastatic transitional cell carcinoma of the urothelium treated with VEGF Trap.

II. Determine the time to progression in patients treated with this drug. III. Determine overall survival of patients treated with this drug. IV. Determine the tolerability and safety of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection periodically during study for pharmacokinetic/pharmacodynamic correlative studies.

After completion of study treatment, patients are followed periodically.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 2014
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed transitional cell carcinoma (TCC) of the urothelium

- Must have predominance of transitional histology, but foci of squamous and/or adenocarcinoma histology allowed

- Poorly differentiated transitional cell carcinoma allowed

- TCC of any of the following sites allowed:

- Bladder

- Renal pelvis

- Ureter

- Urethra

- Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan

- Locoregionally advanced or metastatic disease that is not amenable to curative surgery and/or radiotherapy

- Must have received 1 prior systemic chemotherapy regimen containing a platinum compound (e.g., cisplatin, carboplatin, or oxaliplatin) in the neoadjuvant, adjuvant, or metastatic setting

- No evidence of CNS disease, including primary brain tumor or brain metastases

- ECOG performance status 0-2

- Absolute neutrophil count >= 1,000/mm^3

- Platelet count >= 75,000/mm^3

- Bilirubin =< 1.5 times upper limit of normal (ULN)

- AST or ALT =< 2.5 times ULN

- Creatinine =< 2.5 times ULN OR creatinine clearance => 40 mL/min

- Urine protein: creatinine ratio =< 1 OR 24-hour urine protein < 500 mg

- INR =< 1.5 (unless on full-dose warfarin)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for >= 6 months after completion of study treatment

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

- No history of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in the study

- No serious or nonhealing wound, ulcer, or bone fracture

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- No significant traumatic injury within the past 28 days

- No clinically significant cardiovascular disease, including any of the following:

- Myocardial infarction, coronary artery bypass graft, or unstable angina pectoris within the past 6 months

- New York Heart Association class III or IV congestive heart failure

- Serious cardiac arrhythmia requiring medication

- Clinically significant peripheral vascular disease within the past 6 months

- Cerebrovascular accident within the past 6 months

- Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months

- Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg or systolic BP > 180 mm Hg (if diastolic BP < 90 mm Hg) within the past 3 months

- No evidence of bleeding diathesis or coagulopathy

- No uncontrolled intercurrent illness, including, but not limited to, any of the following:

- Ongoing or active infection

- Psychiatric illness or social situation that would preclude study compliance

- Recovered from prior therapy

- Prior biologic or targeted therapies allowed

- No more than 1 prior systemic chemotherapy regimen for metastatic disease

- No prior antiangiogenic therapy primarily targeting the vascular endothelial growth factor pathway

- At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for mitomycin C or nitrosoureas)

- More than 28 days since prior major surgery or open biopsy

- More than 7 days since prior core biopsy

- No concurrent major surgery

- Concurrent full-dose anticoagulants (e.g., warfarin) allowed provided all of the following criteria are met:

- In-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or low molecular weight heparin

- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

- No other concurrent investigational agents

- No concurrent combination antiretroviral therapy for HIV-positive patients

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Adenocarcinoma of the Bladder
  • Carcinoma
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Distal Urethral Cancer
  • Kidney Neoplasms
  • Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Proximal Urethral Cancer
  • Recurrent Bladder Cancer
  • Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
  • Recurrent Urethral Cancer
  • Squamous Cell Carcinoma of the Bladder
  • Stage III Bladder Cancer
  • Stage III Urethral Cancer
  • Stage IV Bladder Cancer
  • Transitional Cell Carcinoma of the Bladder
  • Ureteral Neoplasms
  • Urethral Cancer Associated With Invasive Bladder Cancer
  • Urethral Neoplasms
  • Urinary Bladder Neoplasms

Intervention

Biological:
ziv-aflibercept
Given IV
Other:
pharmacological study
Correlative studies

Locations

Country Name City State
United States City of Hope Duarte California

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor Response Rate Response rate (RR) and progression free survival (PFS) were assessed in a 2-stage accrual design (22+18). A maximum of 40 patients were to be accrued to rule out a null hypothesized RR of 4% and PFS of 3 months versus alternative of 15% RR and 5.4 months PFS (corresponding to 4 month PFS of 40% vs 60%) with a=0.12 and ß=0.19. If no more than 1 objective response (no more than 4.5%), and no more than 10 instances of 4-month PFS (no more than 45%), were observed among the initial 22 patients, the study would be terminated early and declared negative. Tumor response was evaluated by CT or MRI using RECIST v1.0 criteria.
Responders were confirmed partial or complete responses to treatment.
From the start of the treatment until disease progression or recurrence, assessed up to 4 years No
Primary Progression-free Survival (PFS) Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions PFS using the product-limit method of Kaplan and Meier. From start of treatment to time of progression, assessed up to 4 months No
See also
  Status Clinical Trial Phase
Terminated NCT02122172 - Afatinib in Advanced Refractory Urothelial Cancer Phase 2
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01938573 - Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Phase 1/Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Terminated NCT00112905 - Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Phase 2
Terminated NCT00072137 - Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Phase 1
Completed NCT00072150 - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Phase 2
Completed NCT00028756 - Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Phase 3
Terminated NCT00003452 - Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder Phase 2
Completed NCT00003167 - Gene Therapy in Treating Patients With Advanced Bladder Cancer Phase 1
Completed NCT00005831 - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Phase 2
Completed NCT00021099 - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Phase 2
Terminated NCT01382706 - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Phase 2
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Terminated NCT01954173 - Adjuvant Radiation for High Risk Bladder Cancer N/A
Terminated NCT00004856 - Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Terminated NCT01282333 - Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer Phase 1
Completed NCT01828736 - Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma Phase 2
Terminated NCT02316548 - Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer Phase 2